Skip to main content

Advertisement

Figure 6 | Journal of Translational Medicine

Figure 6

From: Identification of novel epitopes from human papillomavirus type 18 E7 that can sensitize PBMCs of multiple HLA class I against human cervical cancer

Figure 6

Truncated peptides of HPV-18 E7 81–95 (#21) and E7 84–99 (#23) induced the peptide-specific cytotoxicity. PBMCs were sensitized with truncated peptides and tested for cytotoxicity using the 51Cr release assay against HLA-matched, truncated peptide-loaded EBV-BLCs. In HLA-A*02:01, truncated peptides #21-1, #21-8, #21-10 and #23-10-sensitized CTLs lysed more EBV-BLCs loaded with same peptide, respectively, than negative control (A,B), In HLA-A*24:02, #21-1, #21-8, #21-10 and #23-9, #23-10-sensitized CTLs lysed more EBV-BLCs loaded with same peptide, respectively, than negative control (C,D). In HLA-A*11:01, #21-1, #21-10 and #23-10-sensitized CTLs lysed more EBV-BLCs loaded with same peptide, respectively, than negative control (E,F). In HLA-A*33:03, #21-1, #21-10 and #23-10-sensitized CTLs lysed more EBV-BLCs loaded with same peptide, respectively, than negative control (G,H). PBMCs sensitized with truncated-peptide and EBV-BCLs loaded with no peptide were used as the negative control. Data are representative of at least three independent experiments using PBMCs from HLA-A*02:01, HLA-A*24:02, HLA-A*11:01, HLA-A*33:03 subjects. Data are presented as mean (point) ± standard error (bar).

Back to article page